Clinical Trials Logo

Hematopoietic System--Cancer clinical trials

View clinical trials related to Hematopoietic System--Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT03687463 Enrolling by invitation - Clinical trials for Hematopoietic System--Cancer

Modified Post-Transplant Cyclophosphamide Regimen for Children With Juvenile Myelomonocytic Leukemia

Start date: April 10, 2015
Phase:
Study type: Observational [Patient Registry]

Hematopoietic stem cell transplantation (HSCT) is the only curative option for most of juvenile myelomonocytic leukemia (JMML). However, relapse after HSCT severely influence the long-term overall survival (OS). Researches demonstrate that these malignant myeloid disorders is a particular responsiveness to epigenetic therapy with the DNA-hypomethylating agents decitabine. However, hypomethylating therapy does not eradicate the malignant clone in JMML and an emerging concept with intriguing potential is the combination of hypomethylating therapy and HSCT. Graft-versus-host disease (GVHD) is major complication after HSCT as a threshold of the quality of patient life. Many data indicate that post -transplant cyclophosphamide (PT/Cy) is an effective method to control the occurrence of GVHD.

NCT ID: NCT03654703 Enrolling by invitation - Clinical trials for Hematopoietic System--Cancer

Improved Post-Transplant Cyclophosphamide Regimens for Pediatric Patients With Refractory AML

Start date: March 1, 2015
Phase: Phase 2
Study type: Interventional

No more datas about post-transplant cyclophosphamide (PT/Cy) used in pediatric refractory acute myeloid leukemia (R-AML)patients. Investigators reasoned that this group of patients if they have been treated with ablative conditioning regimens for HSCT combined with PT/Cy, under the rapid of immune reconstitution will have better outcomes.